115 related articles for article (PubMed ID: 27091234)
1. The experience of accommodating privacy restrictions during implementation of a large-scale surveillance study of an osteoporosis medication.
Midkiff KD; Andrews EB; Gilsenan AW; Deapen DM; Harris DH; Schymura MJ; Hornicek FJ
Pharmacoepidemiol Drug Saf; 2016 Aug; 25(8):960-8. PubMed ID: 27091234
[TBL] [Abstract][Full Text] [Related]
2. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years.
Andrews EB; Gilsenan AW; Midkiff K; Sherrill B; Wu Y; Mann BH; Masica D
J Bone Miner Res; 2012 Dec; 27(12):2429-37. PubMed ID: 22991313
[TBL] [Abstract][Full Text] [Related]
3. The Forteo Patient Registry linkage to multiple state cancer registries: study design and results from the first 8 years.
Gilsenan A; Harding A; Kellier-Steele N; Harris D; Midkiff K; Andrews E
Osteoporos Int; 2018 Oct; 29(10):2335-2343. PubMed ID: 29978254
[TBL] [Abstract][Full Text] [Related]
4. Safety and effectiveness of daily teriparatide in a prospective observational study in patients with osteoporosis at high risk of fracture in Japan: final report.
Nishikawa A; Ishida T; Taketsuna M; Yoshiki F; Enomoto H
Clin Interv Aging; 2016; 11():913-25. PubMed ID: 27462147
[TBL] [Abstract][Full Text] [Related]
5. Teriparatide Did Not Increase Adult Osteosarcoma Incidence in a 15-Year US Postmarketing Surveillance Study.
Gilsenan A; Midkiff K; Harris D; Kellier-Steele N; McSorley D; Andrews EB
J Bone Miner Res; 2021 Feb; 36(2):244-251. PubMed ID: 32990990
[TBL] [Abstract][Full Text] [Related]
6. Initial experience with teriparatide in the United States.
Gold DT; Pantos BS; Masica DN; Misurski DA; Marcus R
Curr Med Res Opin; 2006 Apr; 22(4):703-8. PubMed ID: 16684431
[TBL] [Abstract][Full Text] [Related]
7. Pediatric registries at the Food and Drug Administration: design aspects that increase their likelihood of success.
Winiecki SK; Tejero-Taldo MI; Avant D; Murphy D; McMahon AW
Pharmacoepidemiol Drug Saf; 2016 May; 25(5):602-5. PubMed ID: 26687996
[TBL] [Abstract][Full Text] [Related]
8. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005-2013.
Bouvy JC; Blake K; Slattery J; De Bruin ML; Arlett P; Kurz X
Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1442-1450. PubMed ID: 28345151
[TBL] [Abstract][Full Text] [Related]
9. Teriparatide [human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis.
Tashjian AH; Gagel RF
J Bone Miner Res; 2006 Mar; 21(3):354-65. PubMed ID: 16491282
[No Abstract] [Full Text] [Related]
10. Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis.
Menter A; Thaçi D; Papp KA; Wu JJ; Bereswill M; Teixeira HD; Rubant S; Williams DA
J Am Acad Dermatol; 2015 Sep; 73(3):410-9.e6. PubMed ID: 26190240
[TBL] [Abstract][Full Text] [Related]
11. Japan Fracture Observational Study (JFOS): patient characteristics and interim data on the use of daily teriparatide in Japanese patients with osteoporosis.
Soen S; Fujiwara S; Takayanagi R; Sato M; Tsujimoto M; Yamamoto T; Enomoto H; Krege JH
Curr Med Res Opin; 2015; 31(9):1771-9. PubMed ID: 26189932
[TBL] [Abstract][Full Text] [Related]
12. Potential impact of the HIPAA privacy rule on data collection in a registry of patients with acute coronary syndrome.
Armstrong D; Kline-Rogers E; Jani SM; Goldman EB; Fang J; Mukherjee D; Nallamothu BK; Eagle KA
Arch Intern Med; 2005 May; 165(10):1125-9. PubMed ID: 15911725
[TBL] [Abstract][Full Text] [Related]
13. Compliance and persistence with treatment with parathyroid hormone for osteoporosis. A Danish national register-based cohort study.
Thorsteinsson AL; Vestergaard P; Eiken P
Arch Osteoporos; 2015; 10():35. PubMed ID: 26427867
[TBL] [Abstract][Full Text] [Related]
14. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
Leder BZ; Tsai JN; Uihlein AV; Wallace PM; Lee H; Neer RM; Burnett-Bowie SA
Lancet; 2015 Sep; 386(9999):1147-55. PubMed ID: 26144908
[TBL] [Abstract][Full Text] [Related]
15. Nonuremic calciphylaxis in a patient with rheumatoid arthritis and osteoporosis treated with teriparatide.
Dominguez AR; Goldman SE
J Am Acad Dermatol; 2014 Feb; 70(2):e41-2. PubMed ID: 24438979
[No Abstract] [Full Text] [Related]
16. Teriparatide: new indication. During corticosteroid therapy: no fewer clinical fractures. Unnecessarily inconvenient.
Prescrire Int; 2009 Aug; 18(102):159. PubMed ID: 19743573
[No Abstract] [Full Text] [Related]
17. Post-approval Studies for Rare Disease Treatments and Orphan Drugs.
Maier WC; Christensen RA; Anderson P
Adv Exp Med Biol; 2017; 1031():197-205. PubMed ID: 29214573
[TBL] [Abstract][Full Text] [Related]
18. Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis.
Wallach JD; Egilman AC; Dhruva SS; McCarthy ME; Miller JE; Woloshin S; Schwartz LM; Ross JS
BMJ; 2018 May; 361():k2031. PubMed ID: 29794072
[TBL] [Abstract][Full Text] [Related]
19. Vertebral fracture risk after once-weekly teriparatide injections: follow-up study of Teriparatide Once-Weekly Efficacy Research (TOWER) trial.
Sugimoto T; Shiraki M; Nakano T; Kishimoto H; Ito M; Fukunaga M; Hagino H; Sone T; Kuroda T; Nakamura T
Curr Med Res Opin; 2013 Mar; 29(3):195-203. PubMed ID: 23259702
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Bone Mineral Density in Lumbar Spine and Fracture Rate among Eight Drugs in Treatments of Osteoporosis in Men: A Network Meta-Analysis.
Chen LX; Zhou ZR; Li YL; Ning GZ; Zhang TS; Zhang D; Feng SQ
PLoS One; 2015; 10(5):e0128032. PubMed ID: 26010450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]